While most of the MO would hold treatment and restart when the counts recover, the faculty members generally stop therapy. Dr Kahl will also consider the selective use of pegfilgrastim and will then reinstitute treatment if counts increase sufficiently.

Grant C et al. Neutropenia associated with rituximab therapy. Curr Opin Hematol 2011;18(1):49-54. Abstract

Tesfa D, Palmblad J. Late-onset neutropenia following rituximab therapy: Incidence, clinical features and possible mechanisms. Expert Rev Hematol 2011;4(6):619-25. Abstract